<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">10559</article-id><article-id pub-id-type="doi">10.7554/eLife.10559</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Epidemiology and Global Health</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>How competition governs whether moderate or aggressive treatment minimizes antibiotic resistance</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-31481"><name><surname>Colijn</surname><given-names>C</given-names></name><aff><institution content-type="dept">Department of Mathematics</institution>, <institution>Imperial College London</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country><email>c.colijn@imperial.ac.uk</email></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-31597"><name><surname>Cohen</surname><given-names>T</given-names></name><aff><institution content-type="dept">School of Public Health</institution>, <institution>Yale University</institution>, <addr-line><named-content content-type="city">New Haven</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-5614"><name><surname>Doebeli</surname><given-names>Michael</given-names></name><role>Reviewing editor</role><aff><institution>University of British Columbia</institution>, <country>Canada</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>22</day><month>09</month><year>2015</year></pub-date><volume>4</volume><elocation-id>e10559</elocation-id><supplementary-material><ext-link xlink:href="elife-10559-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material><history><date date-type="received"><day>03</day><month>08</month><year>2015</year></date><date date-type="accepted"><day>18</day><month>09</month><year>2015</year></date></history><permissions><copyright-statement>Â© 2015, Colijn &amp; Cohen</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Colijn &amp; Cohen</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><p>Understanding how our use of antimicrobial drugs shapes future levels of drug resistance is crucial. Recently there has been debate over whether an aggressive (i.e. high dose) or more moderate (i.e. lower dose) treatment of individuals will most limit the emergence and spread of resistant bacteria. Here we demonstrate how one can understand and resolve these apparently contradictory conclusions. We show that a key determinant of which treatment strategy will perform best at the individual level is the extent of effective competition between resistant and sensitive pathogens within a host. We  extend our analysis to the community level, exploring the spectrum between strict inter-strain competition and strain independence. From this perspective as well, we find that the magnitude of effective competition between resistant and sensitive strains determines whether an aggressive approach or moderate approach minimizes the burden of resistance in the population.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Other</kwd></kwd-group></article-meta></front><back><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group></back></article>